Germany's Merck KGaA has invested $334 million to open a biopharmaceutical plant in Daejeon, South Korea, marking its largest life science investment in the Asia-Pacific region. The 44,500-square-meter facility will produce critical materials for biopharmaceutical development and manufacturing, aiming to strengthen the supply chain for pharmaceutical companies in the region.